---
id: 216
title: Cellulitis and Erysipelas
category: clinical_syndromes
subcategory: skin_soft_tissue
tags: [cellulitis, erysipelas, streptococcus, staphylococcus, beta-lactam, MRSA]
difficulty: medium
---

## Question

How are cellulitis and erysipelas managed? Use **"β-Lactam (Cefazolin/Cephalexin) × 5d, Add MRSA Coverage if Purulent/Abscess"** framework.

## Answer

### **Definitions:**

**Cellulitis:**
- **Diffuse skin/subcutaneous tissue infection**
- **Ill-defined borders, deeper dermis/subcutaneous involvement**

**Erysipelas:**
- **Superficial dermis/lymphatic infection**
- **Well-demarcated, raised borders, bright red, intensely tender**
- **Often involves face**

### **Microbiology:**

**Non-Purulent Cellulitis/Erysipelas:**
- ***Streptococcus pyogenes* (Group A Strep)** - most common
- ***Streptococcus agalactiae* (Group B Strep)**
- ***S. aureus* (MSSA)** - less common

**Purulent Cellulitis/Abscess:**
- ***S. aureus* (MSSA/MRSA)** - most common (80-90%)

**Special Situations:**
- **Freshwater exposure:** *Aeromonas hydrophila*
- **Seawater exposure:** *Vibrio vulnificus* (especially shellfish, cirrhosis)
- **Animal bite:** *Pasteurella multocida*, *Capnocytophaga*
- **Human bite:** Streptococci, anaerobes, *Eikenella corrodens*
- **Immunocompromised:** Gram-negatives, *Pseudomonas*

### **Clinical Presentation:**

**Cellulitis:**
- **Erythema, warmth, swelling, tenderness**
- **Ill-defined borders**
- **Fever** (variable, 25-50%)
- **Regional lymphadenopathy**

**Erysipelas:**
- **Sharply demarcated, raised, bright red plaque**
- **"Orange peel" appearance** (peau d'orange)
- **Often face (butterfly distribution)**
- **Fever, systemic symptoms** (more common than cellulitis)

### **Diagnosis:**

**Clinical Diagnosis:**
- **Usually clinical** (no labs or cultures routinely needed)

**When to Obtain Cultures:**
- **Blood cultures:** If severe systemic symptoms, immunocompromised, concern for bacteremia (positive <5% in routine cellulitis)
- **Aspirate/tissue culture:** NOT routinely recommended (low yield)
- **Abscess culture:** If purulent drainage present (send for culture, Gram stain)

**Imaging:**
- **NOT routinely needed**
- **Ultrasound/CT/MRI:** If concern for abscess, necrotizing fasciitis, osteomyelitis

### **Treatment:**

**Non-Purulent Cellulitis (No Abscess):**

**Outpatient (Mild-Moderate):**
- **Cephalexin 500mg PO QID × 5 days** (first-line)
- **Dicloxacillin 500mg PO QID × 5 days**
- **Alternatives:**
  - **Clindamycin 300-450mg PO TID × 5 days** (if PCN allergy)
  - **Amoxicillin-clavulanate 875mg PO BID × 5 days**

**Inpatient (Severe):**
- **Cefazolin 1-2g IV q8h**
- **Nafcillin 2g IV q4h**
- **Alternatives:**
  - **Vancomycin 15-20 mg/kg IV q8-12h** (if PCN allergy or MRSA risk)
  - **Clindamycin 600-900mg IV q8h**

**Purulent Cellulitis/Abscess (MRSA Coverage):**

**Outpatient:**
- **TMP-SMX DS PO BID × 5-7 days** (first-line)
- **Doxycycline 100mg PO BID × 5-7 days**
- **Clindamycin 300-450mg PO TID × 5-7 days** (if local resistance <10%)

**Inpatient:**
- **Vancomycin 15-20 mg/kg IV q8-12h**
- **Alternatives:** Daptomycin 4-6 mg/kg IV daily, linezolid 600mg PO/IV BID

**Abscess Management:**
- **Incision and drainage (I&D)** = PRIMARY treatment
- **Antibiotics NOT always needed** if I&D performed and no surrounding cellulitis
- **Add antibiotics if:** Extensive surrounding cellulitis, systemic symptoms, immunocompromised, failed I&D alone

**Duration:**
- **5 days** (adequate for most uncomplicated cellulitis)
- **7-10 days** (if severe, slow response, immunocompromised)

### **Special Situations:**

**Erysipelas:**
- **β-lactam** (penicillin, cefazolin, cephalexin) × 5 days
- **PCN G 2-4 million units IV q4-6h** (if severe)

**Recurrent Cellulitis:**
- **Identify/treat predisposing factors:** Lymphedema, tinea pedis, venous stasis, obesity
- **Prophylaxis:** Penicillin VK 250-500mg PO daily OR benzathine PCN G 1.2 million units IM monthly (if ≥3-4 episodes/year)

**Facial Cellulitis (Periorbital/Orbital):**
- **Periorbital (preseptal):** Cephalexin/cefazolin (cover *S. pyogenes*, *S. aureus*)
- **Orbital (postseptal):** HOSPITALIZE, vancomycin + ceftriaxone (cover MRSA + *S. pneumoniae*, *H. influenzae*), ophthalmology consult

**Water Exposure:**
- **Freshwater (***Aeromonas***):** Doxycycline 100mg BID + ciprofloxacin 500mg BID
- **Seawater (***Vibrio***):** Doxycycline 100mg BID + ceftriaxone 2g IV daily (if cirrhosis, high mortality)

**Animal Bite:**
- **Amoxicillin-clavulanate 875mg PO BID × 5-7 days**
- **If PCN allergy:** Doxycycline + metronidazole OR moxifloxacin

**Immunocompromised:**
- **Broad-spectrum coverage:** Vancomycin + pip-tazo (cover MRSA + Gram-negatives)

### **Admission Criteria:**

**Hospitalize if:**
- **Hemodynamic instability, sepsis**
- **Severe local signs** (rapidly progressive, bullae, crepitus, violaceous color)
- **Concern for necrotizing fasciitis** (pain out of proportion, crepitus, bullae, systemic toxicity)
- **Failed outpatient therapy**
- **Immunocompromised** (neutropenia, transplant)
- **Comorbidities** (diabetes, cirrhosis, renal failure)

### **Complications:**

- **Necrotizing fasciitis** (rare, <1%)
- **Bacteremia, sepsis**
- **Abscess formation**
- **Lymphangitis, lymphedema**

## Key Points

### **Non-Purulent = β-Lactam (Strep Coverage):**
- **Cephalexin 500mg QID × 5 days** (outpatient)
- **Cefazolin 1-2g IV q8h** (inpatient)
- **Covers *S. pyogenes*, *S. agalactiae***

### **Purulent/Abscess = MRSA Coverage:**
- **TMP-SMX DS BID × 5-7 days** (outpatient)
- **Vancomycin** (inpatient)
- **I&D = primary treatment** for abscess

### **5 Days Duration:**
- **Adequate for most uncomplicated cellulitis**
- **Extend to 7-10 days** if severe, slow response

### **Do NOT Routinely Culture:**
- **Clinical diagnosis**
- **Blood cultures <5% positive** (only if severe, immunocompromised)

### **Erysipelas = Penicillin/Cefazolin:**
- ***S. pyogenes*** most common
- **Well-demarcated, raised, bright red**

### **Clinical Pearls:**
- **Non-purulent:** Cephalexin 500mg QID × 5 days (β-lactam for Strep)
- **Purulent/abscess:** I&D + TMP-SMX/doxycycline (MRSA coverage)
- **5 days adequate** for uncomplicated cellulitis
- **Do NOT routinely culture** (clinical diagnosis)
- **Erysipelas:** Well-demarcated, raised (penicillin/cefazolin)
- **Recurrent:** Treat predisposing factors (tinea pedis, lymphedema), prophylaxis if ≥3-4 episodes/year

## Sources

- [IDSA: Skin and Soft Tissue Infection Guidelines 2024]
- [Cochrane: Duration of Antibiotics for Cellulitis 2024]

## Media

N/A
